ImmunityBio, Inc.

IBRX · Mid cap · Calculated market cap · $10.0B · as of 2026-09-30

Company Stats

Market Cap: $10.0B; as of Sep 30, 2026
Shares Outstanding: 1.1B
Free Float: 67.7%

Income Statement

Revenue: $113.3M
Operating Income: -$256.0M
Net Income: -$351.4M
EBITDA: -$240.5M
Non-cash Impairment: $14.0M
Revenue Growth, 3Y: 678.6%
FCF Margin, 3Y Avg: -22284.6%
FCF Margin, Worst Year: -63881.2%

Cash Flow

Free Cash Flow: -$308.8M
FCF Yield: -3.1%
Owner FCF Yield: -3.5%

Balance Sheet

Cash & Equivalents: $88.3M

Returns & Capital

SBC, 3Y Avg: $40.1M

Cash Flow by Year

Year	Revenue	FCF	Margin
FY2025	$113.3M	-$308.8M	-272.6%
FY2024	$14.7M	-$398.1M	-2700.1%
FY2023	$622,000	-$397.3M	-63881.2%
FY2022	$240,000	-$415.7M	-173196.2%
FY2021	$934,000	-$308.0M	-32974.5%

Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.

Company RSS